Optimizing HFrEF Patients Using BaroStim and CardioMems

Recruiting now · Phase 2/Phase 3

Conditions studied: Heart Failure NYHA Class III

In brief

The goal of this study is to utilize CardioMems (measurement of pulmonary artery diastolic pressure) to assess BaroStim. At the time of CardioMems insertion, patients will be screened for candidacy to receive a BaroStim device. Patients will be followed for 3 months after the CardioMems insertion before undergoing insertion of a Barostim. Patients who have undergone a CardioMems, will be eligible for enrollment after 3 months of medication management and optimization. Patients will be followed for 1 year after insertion of Barostim.

Key facts

Study ID

NCT07399587

Run by

Northwell Health

People needed

15

Starts

2025-01-17

Expected to finish

2029-12-31

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, ages 18-80 years
• Diagnosed with NYHA Class III Heart Failure with LVEF<35%
• Able to tolerate oral medications for guideline directed medical therapy titration period
• Have undergone insertion of CardioMems and BaroStim devices per standard of care.
• It is a standard of care to recommend that females of reproductive potential use highly effective contraception, because of the teratogenic potential of many medications used to treat HFrEF. In addition, withdrawal of GDMT during pregnancy may reverse the positive remodeling and lead to life threatening worsening of heart failure. Women of child-bearing age need to agree to use such a method during study participation and indefinitely after the end of the study.

You may not qualify if…

• Individuals ineligible for either CardioMems or BaroStim devices.
• NT-proBNP >1600 mg/dL
• Indicated for CRT-D device (left bundle branch block)
• Initial 6-minute walk test distance less than 140 m
• Left ventricular assist device (LVAD)
• History of carotid vascular procedure (carotid endarterectomy)
• Pregnancy or lactation
• Known allergic reactions to components of the BaroStim or CardioMems insertion or guideline directed medical therapy for heart failure
• Febrile illness within 30 days of study enrollment
• Treatment with another investigational drug or other intervention within 1 year
• Current smoker or tobacco use within 1 year
• Enrolled in any other CVRx funded study, including investigator-initiated research, registries, or other pre- or post-market studies.
• Vulnerable individuals as outlined below

Where it is running

• Peconic Bay Medical Center — Riverhead, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.